Time filter

Source Type

Lee S.L.,U.S. Food and Drug Administration | Saluja B.,U.S. Food and Drug Administration | Garcia-Arieta A.,Spanish Agency for Medicines and Health Care Products | Santos G.M.L.,Brazilian Health Surveillance Agency Anvisa | And 7 more authors.
AAPS Journal | Year: 2015

This article describes regulatory approaches for approval of “generic” orally inhaled drug products (OIDPs) in the United States, European Union, Brazil, China and India. While registration of a generic OIDP in any given market may require some documentation of the formulation and device similarity to the “original” product as well as comparative testing of in vitro characteristics and in vivo performance, the specific documentation approaches, tests and acceptance criteria vary by the country. This divergence is due to several factors, including unique cultural, historical, legal and economic circumstances of each region; the diverse healthcare and regulatory systems; the different definitions of key terms such as “generic” and “reference” drug; the acknowledged absence of in vitro in vivo correlations for OIDPs; and the scientific and statistical issues related to OIDP testing (such as how best to account for the batch-to-batch variability of the Reference product, whether to use average bioequivalence or population bioequivalence in the statistical analysis of results, whether to use healthy volunteers or patients for pharmacokinetic studies, and which pharmacodynamic or clinical end-points should be used). As a result of this discrepancy, there are ample opportunities for the regulatory and scientific communities around the world to collaborate in developing more consistent, better aligned, science-based approaches. Moving in that direction will require both further research and further open discussion of the pros and cons of various approaches. © 2015, American Association of Pharmaceutical Scientists.

Hou S.,Sichuan Purity Pharmaceutical Technology Co. | Wu J.,Sichuan Purity Pharmaceutical Technology Co. | Li X.,Sichuan Purity Pharmaceutical Technology Co. | Shu H.,Sichuan Purity Pharmaceutical Technology Co.
Asian Journal of Pharmaceutical Sciences | Year: 2015

The formulation and device collectively constitute an inhalation drug product. Development of inhaled drugs must consider the compatibility between formulation and device in order to achieve the intended pharmaceutical performance and usability of the product to improve patient compliance with treatment instruction. From the points of formulation, device and patient use, this article summarizes the inhalation drugs, including pressurized metered dose inhaler (pMDI), dry powder inhaler (DPI), and nebulizer that are currently available in the US and UK markets. It also discusses the practical considerations for the development of inhalers and provides an update on the corresponding regulations of the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency). © 2015 The Authors.

Loading Sichuan Purity Pharmaceutical Technology Co. collaborators
Loading Sichuan Purity Pharmaceutical Technology Co. collaborators